CDK4/6 inhibitor-based endocrine therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CDK4/6 inhibitor-based endocrine therapy, covering 2026-04-02 to 2026-04-02. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype [Phase 2]